|
1
|
World Health Organization (WHO), .
GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence
Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspxAccessed.
April 30–2015
|
|
2
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lamouille S, Subramanyam D, Blelloch R and
Derynck R: Regulation of epithelial-mesenchymal and
mesenchymal-epithelial transitions by microRNAs. Curr Opin Cell
Biol. 25:200–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schetter AJ, Okayama H and Harris CC: The
role of microRNAs in colorectal cancer. Cancer J. 18:244–252. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Melton C, Judson RL and Blelloch R:
Opposing microRNA families regulate self-renewal in mouse embryonic
stem cells. Nature. 463:621–626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yoo AS, Sun AX, Li L, et al:
MicroRNA-mediated conversion of human fibroblasts to neurons.
Nature. 476:228–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rottiers V and Näär AM: MicroRNAs in
metabolism and metabolic disorders. Nat Rev Mol Cell Biol.
13:239–250. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rossi S, Di Narzo AF, Mestdagh P, et al:
microRNAs in colon cancer: A roadmap for discovery. FEBS Lett.
586:3000–3007. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartels CL and Tsongalis GJ: MicroRNAs:
Novel biomarkers for human cancer. Ann Biol Clin (Paris).
68:263–272. 2010.(In French). PubMed/NCBI
|
|
10
|
Tsuchida A, Ohno S, Wu W, et al: miR-92 is
a key oncogenic component of the miR-17-92 cluster in colon cancer.
Cancer Sci. 102:2264–2271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fan MQ, Huang CB, Gu Y, Xiao Y, Sheng JX
and Zhong L: Decrease expression of microRNA-20a promotes cancer
cell proliferation and predicts poor survival of hepatocellular
carcinoma. J Exp Clin Cancer Res. 32:212013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang CC, Yang YJ, Li YJ, et al:
MicroRNA-17/20a functions to inhibit cell migration and can be used
a prognostic marker in oral squamous cell carcinoma. Oral Oncol.
49:923–931. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang Y, Liu C, Yang J, et al: MiR-20a
triggers metastasis of gallbladder carcinoma. J Hepatol.
59:518–527. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jeong WJ, Cha PH and Choi KY: Strategies
to overcome resistance to epidermal growth factor receptor
monoclonal antibody therapy in metastatic colorectal cancer. World
J Gastroenterol. 20:9862–9871. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schetter AJ, Leung SY, Sohn JJ, et al:
MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Malzkorn B, Wolter M, Liesenberg F, et al:
Identification and functional characterization of microRNAs
involved in the malignant progression of gliomas. Brain Pathol.
20:539–550. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Volinia S, Calin GA, Liu CG, et al: A
microRNA expression signature of human solid tumors defines cancer
gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yan H, Wu J, Liu W, Zuo Y, Chen S, Zhang
S, Zeng M and Huang W: MicroRNA-20a overexpression inhibited
proliferation and metastasis of pancreatic carcinoma cells. Hum
Gene Ther. 21:1723–1734. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Diosdado B, van de Wiel MA, Terhaar Sive
Droste JS, et al: MiR-17-92 cluster is associated with 13q gain and
c-myc expression during colorectal adenoma to adenocarcinoma
progression. Br J Cancer. 101:707–714. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu QC, Gao RY, Wu W and Qin HL:
Epithelial-mesenchymal transition and its role in the pathogenesis
of colorectal cancer. Asian Pac J Cancer Prev. 14:2689–2698. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun XJ, Zhang P, Li HH, Jiang ZW, Jiang CC
and Liu H: Cisplatin combined with metformin inhibits migration and
invasion of human nasopharyngeal carcinoma cells by regulating
E-cadherin and MMP-9. Asian Pac J Cancer Prev. 15:4019–4023. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Levi E, Fridman R, Miao HQ, Ma YS, Yayon A
and Vlodavsky I: Matrix metalloproteinase 2 releases active soluble
ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad
Sci USA. 93:7069–7074. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen R, Cui J, Xu C, et al: The
significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence
of hepatocellular carcinoma after curative resection. Ann Surg
Oncol. 19 (Suppl 3):S375–S384. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Y, Bi T, Shen G, et al: Lupeol induces
apoptosis and inhibits invasion in gallbladder carcinoma GBC-SD
cells by suppression of EGFR/MMP-9 signaling pathway.
Cytotechnology. Jul 19–2014.(Epub ahead of print). View Article : Google Scholar
|
|
27
|
Kallakury BV, Karikehalli S, Haholu A,
Sheehan CE, Azumi N and Ross JS: Increased expression of matrix
metalloproteinases 2 and 9 and tissue inhibitors of
metalloproteinases 1 and 2 correlate with poor prognostic variables
in renal cell carcinoma. Clin Cancer Res. 7:3113–3119.
2001.PubMed/NCBI
|
|
28
|
Wang Z, Wang B, Shi Y, et al: Oncogenic
miR-20a and miR-106a enhance the invasiveness of human glioma stem
cells by directly targeting TIMP-2. Oncogene. 34:1407–1419. 2015.
View Article : Google Scholar : PubMed/NCBI
|
